NasdaqGS:CNST

Stock Analysis Report

Executive Summary

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Risks

  • Constellation Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Constellation Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.5%

NasdaqGS:CNST

1.5%

US Biotechs

0.9%

US Market


1 Year Return

-22.2%

NasdaqGS:CNST

-7.3%

US Biotechs

0.3%

US Market

CNST underperformed the Biotechs industry which returned -8% over the past year.

CNST underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

CNSTIndustryMarket
7 Day1.5%1.5%0.9%
30 Day-17.8%2.2%-1.9%
90 Day-24.4%3.5%1.6%
1 Year-22.2%-22.2%-6.5%-7.3%2.6%0.3%
3 Yearn/a8.9%5.2%41.0%31.8%
5 Yearn/a6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is Constellation Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Constellation Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

3.06x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Constellation Pharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Constellation Pharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

Constellation Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Constellation Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Constellation Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Constellation Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Constellation Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

-17.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Constellation Pharmaceuticals is high growth as no revenue estimate data is available.

Constellation Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Constellation Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Constellation Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Constellation Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Constellation Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Constellation Pharmaceuticals performed over the past 5 years?

-36.8%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Constellation Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Constellation Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Constellation Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Constellation Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Constellation Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Constellation Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Constellation Pharmaceuticals's financial position?


Financial Position Analysis

Constellation Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Constellation Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Constellation Pharmaceuticals's level of debt (29.1%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Constellation Pharmaceuticals's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 5.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Constellation Pharmaceuticals has sufficient cash runway for 1.5 years based on current free cash flow.

Constellation Pharmaceuticals has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 25.2% each year.


Next Steps

Dividend

What is Constellation Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Constellation Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Constellation Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Constellation Pharmaceuticals has not reported any payouts.

Unable to verify if Constellation Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Constellation Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Constellation Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Jigar Raythatha 0

2.4yrs

Tenure

US$4,703,254

Compensation

Mr. Jigar Raythatha has been the President, Chief Executive Officer and Director of Constellation Pharmaceuticals, Inc. since March 2017. Mr. Raythatha served as the Chief Business Officer at Jounce Therap ...


CEO Compensation Analysis

Jigar's remuneration is higher than average for companies of similar size in United States of America.

Jigar's compensation has increased whilst company is loss making.


Management Age and Tenure

2.3yrs

Average Tenure

55yo

Average Age

The tenure for the Constellation Pharmaceuticals management team is about average.


Board Age and Tenure

2.3yrs

Average Tenure

63yo

Average Age

The average tenure for the Constellation Pharmaceuticals board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Emma Reeve (58yo)

    Senior VP

    • Tenure: 1.8yrs
    • Compensation: US$1.44m
  • Brenda Sousa (55yo)

    Senior Vice President of Human Resources & Operations

    • Tenure: 2.3yrs
  • Jigar Raythatha

    President

    • Tenure: 2.4yrs
    • Compensation: US$4.70m
  • David Allis

    Co-Founder

    • Tenure: 11.6yrs
  • Karen Valentine (47yo)

    Chief Legal Officer & General Counsel

    • Tenure: 1.1yrs
  • Ron Aldridge (65yo)

    Senior Director of Investor Relations

    • Tenure: 0.0yrs
  • Danny Reinberg

    Co-Founder

    • Tenure: 11.6yrs
  • Yang Shi

    Co-Founder

    • Tenure: 11.6yrs
  • Adrian Senderowicz (55yo)

    Senior VP & Chief Medical Officer

    • Tenure: 2.1yrs
    • Compensation: US$1.13m
  • Patrick Trojer (46yo)

    Chief Scientific Officer

    • Tenure: 0.8yrs

Board Members

  • Tony Evnin (78yo)

    Director

    • Tenure: 11.3yrs
    • Compensation: US$24.37k
  • Bob Tepper (63yo)

    Director

    • Tenure: 11.3yrs
    • Compensation: US$21.64k
  • Mark Goldsmith (57yo)

    Chairman of the Board

    • Tenure: 0.0yrs
    • Compensation: US$204.51k
  • Jigar Raythatha

    President

    • Tenure: 2.4yrs
    • Compensation: US$4.70m
  • David Livingston (77yo)

    Member of the Scientific Advisory Board

    • Tenure: 0.0yrs
  • Scott Lowe

    Member of the Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jim Audia (63yo)

    Director

    • Tenure: 2.1yrs
    • Compensation: US$230.33k
  • Steve Hoerter (48yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: US$177.29k
  • Pam Sharma

    Member of Scientific Advisory Board

    • Tenure: 2.3yrs
  • Robert Schreiber

    Member of Scientific Advisory Board

    • Tenure: 2.3yrs

Company Information

Constellation Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Constellation Pharmaceuticals, Inc.
  • Ticker: CNST
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$205.781m
  • Shares outstanding: 25.82m
  • Website: https://www.constellationpharma.com

Number of Employees


Location

  • Constellation Pharmaceuticals, Inc.
  • 215 First Street
  • Suite 200
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNSTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2018

Biography

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:59
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.